You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 1403 Outcomes following first-line immunotherapy with or without chemotherapy stratified by KRAS mutational status – A real world analysis in patients with advanced NSCLC

Article info

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Other
1403 Outcomes following first-line immunotherapy with or without chemotherapy stratified by KRAS mutational status – A real world analysis in patients with advanced NSCLC
Free

Authors

Citation

Aggarwal C, Nimeiri H, Chen J, et al
1403 Outcomes following first-line immunotherapy with or without chemotherapy stratified by KRAS mutational status – A real world analysis in patients with advanced NSCLC
Journal for ImmunoTherapy of Cancer 2022;10:doi: 10.1136/jitc-2022-SITC2022.1403

Publication history

  • First published November 7, 2022.
Online issue publication 
April 26, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.